Anti-vascular endothelial growth factor for neovascular age-related macular degeneration

Age-related macular degeneration (AMD) is the most common cause of uncorrectable severe vision loss in people aged 55 years and older in the developed world. Choroidal neovascularization (CNV) secondary to neovascular AMD accounts for most AMD-related severe vision loss. Anti-vascular endothelial gr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2014-08, Vol.8 (8), p.CD005139-CD005139
Hauptverfasser:	Solomon, Sharon D, Lindsley, Kristina, Vedula, Satyanarayana S, Krzystolik, Magdalena G, Hawkins, Barbara S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angiogenesis Inhibitors - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized - therapeutic use Aptamers, Nucleotide - therapeutic use Choroidal Neovascularization Humans Intravitreal Injections Macular Degeneration - drug therapy Middle Aged Porphyrins - therapeutic use Randomized Controlled Trials as Topic Ranibizumab Vascular Endothelial Growth Factor A - antagonists & inhibitors Verteporfin Visual Acuity - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!